D-0484-2019 Class III Terminated
FDA drug recall D-0484-2019 was initiated by Lupin Pharmaceuticals Inc. on Feb 1, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification test results in related substance at three-month long term stability study was obtained. The recall status is terminated (terminated Jun 26, 2020). Affected quantity: 43,860 3ml bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 20, 2019
- Initiation Date
- Feb 1, 2019
- Termination Date
- Jun 26, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 43,860 3ml bottles
Product description
Moxifloxacin Ophthalmic Solution USP, 0.5%, 3 mL dropper bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 Manufactured by: lupin Limited Pithampur (M.P.) 454 775 India. NDC 68180-422-01
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification test results in related substance at three-month long term stability study was obtained.
Distribution pattern
Product was distributed by 5 wholesalers, 6 drug chains, 4 mail order pharmacies and 1 mail order pharmacy/supermarket who may have further distribute the product throughout the United States.
Code information
Lot Numbers: H705562, H705563, EXP. 11/2019; H800616, EXP. 01/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0484-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026